Melanotan II: Research Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) originally developed in the 1980s at the University of Arizona as part of a research program to investigate photoprotection through induced skin pigmentation. Unlike its successor bremelanotide (PT-141), which was engineered for receptor selectivity, Melanotan II is a non-selective melanocortin receptor agonist with significant activity at MC1R (tanning), MC3R, MC4R (sexual arousal), and MC5R. It has never been approved by the FDA, EMA, TGA, or any other major drug regulatory authority for any indication. The FDA has issued warnings regarding its sale, and regulatory agencies in the UK, Australia, and New Zealand have taken enforcement action against its distribution.

What is Melanotan II?

Melanotan II is a cyclic lactam analogue of α-MSH with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its molecular weight is approximately 1024 Da. The cyclic structure confers metabolic stability relative to linear α-MSH but also contributes to the potent, broad-spectrum receptor activation that distinguishes it from more selective melanocortin compounds. It is sold by research-chemical vendors as a lyophilized powder, typically in 5–10 mg vials, and carries significant regulatory risk in multiple jurisdictions. In Australia, MT-II is a Schedule 4 prescription-only medicine; import for non-prescription purposes is tightly controlled. In the UK, it is not approved and is the subject of enforcement actions.

Mechanism of Action

Melanotan II is a potent, non-selective agonist at melanocortin receptors MC1R through MC5R. The physiological consequences of this broad receptor activation include: (1) MC1R activation on melanocytes, triggering eumelanin synthesis and skin darkening; (2) MC3R and MC4R activation in the hypothalamus, producing sexual arousal effects and appetite suppression; and (3) MC4R activation in the CNS and spinal cord, contributing to spontaneous erections in males. Because MT-II can cross the blood-brain barrier, central effects (sexual arousal, erection, appetite suppression, yawning, fatigue, somnolence) are prominent even at doses that produce mild peripheral tanning.

The non-selectivity of Melanotan II is the root cause of both its broad range of observed effects and its adverse-event profile. MC5R activation is associated with exocrine gland secretion changes, and MC1R agonism raises the theoretical concern — supported by case reports — of promoting melanocyte proliferation and altered pigmented lesions, which has prompted regulatory warnings about melanoma risk in individuals with pre-existing risk factors.

What the Research Shows

The foundational human study is the pilot phase 1 dose-escalation conducted by Dorr et al. and published in Life Sciences in 1996 (PMID 8637402). The study enrolled a small number of healthy male volunteers who received subcutaneous doses on alternating days across a dose range of approximately 10–300 mcg. Two subjects demonstrated increased skin pigmentation after 5 low-dose injections. The highest-dose cohort experienced grade II somnolence and fatigue. No severe adverse events were reported in this small, short-duration study.

Beyond this pilot study, the human evidence base for Melanotan II is sparse and largely limited to older, small-scale studies or case reports. Regulatory concerns have grown around post-marketing safety signals: the FDA issued a warning letter against at least one company (Melanocorp, Inc.) for illegal sale and marketing of Melanotan II as an injectable tanning product, citing absence of approved NDA and unsubstantiated safety claims. Case reports of new or changing pigmented lesions, including melanomas, in Melanotan II users have been published, though a direct causal link has not been definitively established.

Pharmacokinetics

Detailed human pharmacokinetic data for Melanotan II are limited. The cyclic structure confers greater metabolic stability than linear α-MSH; subcutaneous administration produces systemic absorption with central nervous system effects typically observed within 15–60 minutes, consistent with blood-brain barrier penetration. Duration of central effects (erection, appetite suppression) generally lasts 2–6 hours in reports from the small published literature. No formal PK/PD modeling study comparable to those available for bremelanotide or ipamorelin has been published.

Common Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The pilot phase 1 study by Dorr et al. (1996; PMID 8637402) evaluated subcutaneous doses of approximately 10–300 mcg administered on alternating days in healthy male volunteers. Maintenance dosing was not evaluated in that study. This constitutes the only controlled human dose-ranging data available for Melanotan II. The literature from this pilot study reports subcutaneous administration on alternating days; maintenance dosing was not evaluated.

Storage

Lyophilized Melanotan II should be stored at −20 °C in a light-protected, dry environment. Once reconstituted, the solution should be kept at 2–8 °C. Given the regulatory concerns around this compound, note that importation, sale, or possession may be restricted or illegal in many jurisdictions.

What Melanotan II Is NOT

Melanotan II is not the same compound as PT-141 (bremelanotide). Despite sharing structural ancestry and an overlapping receptor activation profile, bremelanotide was specifically engineered to minimize MC1R activity — eliminating the tanning effect and reducing melanocyte stimulation — while retaining MC3R/MC4R agonism. Bremelanotide is FDA-approved as Vyleesi for HSDD; Melanotan II is not approved for any indication. MT-II is also not Melanotan I (afamelanotide), which is a more selective MC1R agonist approved in the EU for erythropoietic protoporphyria — a different compound with a different structure and clinical indication.

References

Citations for this guide are listed below. All PubMed links resolve to the NCBI abstract page for the referenced article.